ReviewOncogene2004
High-throughput gene silencing using cell arrays.
Review in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 49 citations in OpenAlex.
- Targeting "undruggable" cancer proteins: pharmacological challenges and emerging strategies.Translational cancer research · 2026Review
- Microtubule-stabilizing drugs from marine sponges: focus on peloruside A and zampanolide.Marine drugs · 2010Review
- Efficacy of immobilized polyplexes and lipoplexes for substrate-mediated gene delivery.Biotechnology and bioengineering · 2009Article
- Living-cell microarrays.Annual review of biomedical engineering · 2009Review
- High-throughput mammalian two-hybrid screening for protein-protein interactions using transfected cell arrays.BMC genomics · 2008Article
- [X]uniqMAP: unique gene sequence regions in the human and mouse genomes.BMC genomics · 2006Article
- siRNA-based approaches in cancer therapy.Cancer gene therapy · 2006Review
- Cell array-based intracellular localization screening reveals novel functional features of human chromosome 21 proteins.BMC genomics · 2006Article
- RNA interference: ready to silence cancer?Journal of molecular medicine (Berlin, Germany) · 2006Review
- RNA interference: from gene silencing to gene-specific therapeutics.Pharmacology & therapeutics · 2005Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recently established transfected cell array (TCA) technology has opened new experimental dimensions in the field of functional genomics. Cell arrays allow for transfection of several thousands different DNA molecules in microarray format. The effects of overexpression of hundreds of proteins on cellular physiology can be observed in a single experiment. The TCA technique has also found its application in RNA interference (RNAi) research. Small interfering RNAs (siRNA) as well as plasmid expressing short hairpin RNAs can be transferred into the cells through the process of reverse transfection. The silencing of numerous genes in spatially separated manner can be thus monitored. This review will provide an overview on current concepts concerning combination of cell array and RNAi for high-throughput loss-of-function studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.